Accurate risk assignment in childhood acute lymphoblastic leukaemia is essential to avoid under-or over-treatment. We hypothesized that time-series gene expression profiles (GEPs) of bone marrow samples during remission-induction therapy can measure the response and be used for relapse prediction. We computed the time-series changes from diagnosis to Day 8 of remission-induction, termed Effective Response Metric (ERM-D8) and tested its ability to predict relapse against contemporary risk assignment methods, including National Cancer Institutes (NCI) criteria, genetics and minimal residual disease (MRD). ERM-D8 was trained on a set of 131 patients and validated on an independent set of 79 patients. In the independent blinded test set, unfavourable ERM-D8 patients had >3-fold increased risk of relapse compared to favourable ERM-D8 (5-year cumulative incidence of relapse 38Á1% vs. 10Á6%; P = 2Á5 9 10 À3 ). ERM-D8 remained predictive of relapse [P = 0Á05; Hazard ratio 4Á09, 95% confidence interval (CI) 1Á03-16Á23] after adjusting for NCI criteria, genetics, Day 8 peripheral response and Day 33 MRD. ERM-D8 improved risk stratification in favourable genetics subgroups (P = 0Á01) and Day 33 MRD positive patients (P = 1Á7 9 10
. Patients who harbour high levels of residual disease after remission-induction therapy do considerably poorer, suggesting that intrinsic resistance to remissioninduction therapy is present at diagnosis and causes relapse.
Whole genome gene expression profiling (GEP) can subtype various haematological malignancies like ALL (Yeoh et al, 2002; Haferlach et al, 2010) , acute myeloid leukaemia (Schoch et al, 2002; Valk et al, 2004; Balgobind et al, 2011) and lymphoma (Alizadeh et al, 2000) subgroups with an exceedingly high accuracy of >95%. However, its ability to predict relapse remains to be defined.
We hypothesize that treatment will unmask the intrinsic sensitivity of leukaemic blasts in each patient, providing new insights to treatment response and be useful for relapse prediction. Time-series experiments are widely used in vitro to test response in yeast and cell lines to specific treatments. However, they have yet to be tested clinically for risk assignment in cancer treatment (Rhein et al, 2007) .
We performed 420 time-series GEPs from 210 children (Table I) with newly diagnosed ALL, treated using an ALLBerlin-Frankf€ urt-M€ unster (BFM) backbone, at diagnosis (Day 0) and Day 8 of remission-induction treatment. We devised a novel prognostic factor based on the direction and magnitude of time-series changes between diagnosis and specific points of remission induction, which we termed Effective Response Metric (ERM, Fig 1) . Our results suggest that ERM at Day 8 (ERM-D8) is an independent prognostic factor of relapse.
Methods

Patient and treatment procedure
From July 2002 to December 2014, 210 children with de novo ALL treated in the Ma-Spore ALL 2003 (Yeoh et al, 2012) and ALL 2010 studies, and including nine from the ALL-IC-BFM-2002 study (Stary et al, 2014) , with sufficient banked RNA or cryopreserved bone marrow (BM) cells were enrolled in this study. Patients treated in the Ma-Spore ALL 2003 study were assigned to the training set for ERM-D8 (n = 131; Table I ), and patients in Ma-Spore ALL 2010 and ALL-IC 2002 studies were assigned to the blinded test set (n = 79; Table I ).
Informed consent approved by the respective review boards (DSRB ref: 2004/00275 and 2008/00081) was obtained in accordance with the Declaration of Helsinki. Diagnosis of ALL was confirmed by BM morphology and standard immunophenotyping. Hyperdiploidy was determined either by karyotyping (modal chromosome >50) or by DNA index (≥1Á16). Molecular screening for t(12;21)/ETV6-RUNX1, t (1;19)/TCF3-PBX1, t(9;22)/BCR-ABL1, and t(11q23)/ KMT2A) fusions were performed using quantitative real-time polymerase chain reaction (PCR) (Scurto et al, 1998) . ERG deletion was detected using multiplex ligation-dependent probe amplification (MLPA) P327 iAMP21-ERG probemix (MRC-Holland, Amsterdam, Netherlands). BCR-ABL1-like was identified with the method of Harvey et al (2010) .
Treatment response
All patients were treated using the ALL-BFM backbone. In the Ma-Spore ALL 2003 study (Yeoh et al, 2012) and ALL-IC 2002 protocol (Stary et al, 2014) , patients received upfront intra-thecal methotrexate, followed by 7 days of prednisolone. In Ma-Spore ALL 2010, intravenous vincristine replaced intra-thecal methotrexate at Day 0. A 3-drug dexamethasone-based remission-induction therapy was used for standard-and intermediate-risk patients while high-risk patients received additional daunorubicin in the Ma-Spore studies.
Day 8 poor peripheral blood response (PPR) was defined as persistence of ≥1Á0 9 10 9 blasts/l in the peripheral blood 
Gene expression profiling
Bone marrow mononuclear cells were separated using FicollPaque (GE Healthcare Life Sciences, Piscataway, NJ, USA) density gradient centrifugation. Total RNA was isolated using TRIzol â reagent (Invitrogen, Carlsbad, CA, USA) and purified using RNeasy Mini Kit (Qiagen, Valencia, CA, USA). Paired Day 0 and Day 8 GEPs from the 210 patients were obtained using Affymetrix HG-U133A (n = 39) or HG-U133 Plus 2Á0 (n = 381) array (Affymetrix, Santa Clara, CA, USA), according to the manufacturer's protocol (Table I ). All microarray data are available in the Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc= GSE67684).
Gene expression analyses
Gene expression values were scaled, filtered, log transformed and quantile normalized (Bolstad et al, 2003) as described in Data S1. Additional diagnostic ALL BM GEPs (n = 750) and normal BM GEPs (n = 74) were obtained from the Microarray Innovations in Leukemia (MILE) data set (Haferlach et al, 2010) and were processed similarly.
We developed a novel metric termed Effective Response Metric (ERM) that measures the time-series response to remission-induction in a multidimensional gene expression space, where each dimension is the expression of a probe set. ERM is defined as the shift of the patient's diagnostic GEP along the direction from disease centroid (the median of diagnostic GEPs) to normal centroid (the median of normal BM GEPs; Fig 1) ; see Data S1 for the details and formula of ERM calculation. A large positive ERM is favourable, indicating a large change in GEP towards normal. Technically, ERM is the scalar resolute in the direction from disease centroid to normal centroid.
Performances of ERM calculated with up-regulated probe sets, down-regulated probe sets and combined up-and down-regulated probe sets using the training set were compared. The top 500 down-regulated probe sets at Day 8 performed the best and were selected to build ERM-D8. The best threshold cut-off for ERM-D8 was determined using the training set (n = 131). The same probe sets and threshold were applied to the blinded test set (n = 79).
To further demonstrate that ERM can independently predict outcome and was not subject to any training bias, we used ERM based on differentially expressed genes between lymphoblasts and normal cells. To do so, we selected the top 500 up-regulated probe sets in MILE diagnostic ALL BM GEPs (n = 750) that are differentially expressed compared to normal BM GEPs (n = 74). An alternative ERM-D8 based on leukaemic signature was computed for all the patients with Day 0 and Day 8 GEPs (n = 210).
Statistical analysis
Resistant disease (BM blasts ≥5% at Day 33) is an event at day 1. Cumulative incidence of relapse (CIR, including resistant disease) was compared by Gray's test. Event-free survival (EFS, resistant disease, relapse and death as event) was estimated using Kaplan-Meier methods and compared by log-rank test. Multivariate analyses were made using Fine and Gray proportional sub-distribution hazards model, adjusting for early presenting features: NCI criteria (Smith et al, 1996) , genetics/ molecular subgroup and Day 8 peripheral blood response. Subsequently, we added MRD at Day 33, a later defined prognostic factor. Statistical analysis was performed using R version 2.15.1 (https://www.r-project.org/) for Windows.
Results
Effective Response Metric (ERM) as a novel prognostic factor
The performances of ERM-D8 using up-regulated probe sets, down-regulated probe sets and combined up-and downregulated probe sets at Day 8 were compared using the training set of 131 patients from Ma-Spore ALL 2003. ERM-D8 with down-regulated probe sets alone achieved the best accuracy (Table SI) . Incorporating up-regulated genes did not improve prediction accuracy. The best ERM threshold cutoff obtained on the training set was 11Á99. A patient was assigned to ERM favourable if ERM-D8 > 11Á99, and was otherwise classified as ERM unfavourable. We then validated the performance of ERM-D8 with down-regulated probe sets in the blinded test set (n = 79, Table I ).
In the training set (Fig 2A) , unfavourable ERM-D8 patients (n = 51) had a 3-fold increased risk of relapse compared to favourable ERM-D8 (n = 80; 5-year CIR 45Á3% vs. 14Á9%; P = 1Á1 9 10 À4 ). Similarly, in the blinded test set (Fig 2C) , unfavourable ERM-D8 patients (n = 21) had a >3-fold increased risk of relapse compared to ERM-D8 favourable (n = 58; 5-year CIR 38Á1% vs. 10Á6%; P = 2Á5 9 10 À3 ).
For EFS, ERM-D8 was strongly predictive of outcome in both the training set (P = 1Á0 9 10 À3 ; Fig 2B) and the test set (P = 7Á9 9 10 À4 ; Fig 2D) . To demonstrate that ERM is not merely a surrogate marker of MRD at day 8, we compared ERM-D8 versus PCR-based Day 8 MRD in 75 randomly selected patients ( Figure S1A ). The majority of patients had very high PCR MRD (≥25%; n = 54) at day 8 and this did not confer higher risk of relapse (P = 0Á64; Figure S1B), whereas patients with unfavourable ERM-D8 had a 3-fold increase risk of relapse (P = 7Á3 9 10 À3 ; Figure S1D ).
Similarly, the percentage of lymphoblasts (M3 BM) at Day 8 BM by light microscopy did not predict outcome ( Figure S2 ) and there was only a weak association between Day 8 BM blast count with ERM-D8 ( Figure S3 ). We performed gene ontology (GO) analysis separately on the top 500 down-and up-regulated probe sets using WEBbased Gene SeT AnaLysis Toolkit (Wang et al, 2013) (Table SII and Figures S4-S5 ). Amazingly, 9 out of 10 of the top GO terms for down-regulated genes in ERM-D8 involved DNA, chromosome and nuclear functions, suggesting that successful shutting down of the cell replicative machinery in lymphoblasts after remission induction therapy is the basis of favourable ERM-D8. Similarly, KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway (Kanehisa & Goto, 2000) analysis showed cell replication pathways involving DNA replication and cell cycle were the only two pathways that were significantly enriched in the top 500 down-regulated probe sets (Table SIII and Figures S6-S7 ). These data suggest that ERM-D8 sums up the degree of genome-wide inhibition of cell proliferation after therapy in a single metric, providing a novel way to measure early "inhibition of proliferation" response to treatment. This metric of functional cellular proliferative inhibition differs from D8 PB prednisolone response or MRD, which measures the amount of remaining lymphoblasts, which is a late measure.
We validated ERM values in 22 patients using another platform QuantiGene Plex (Panomics/Affymetrix Inc., Fremont, CA) on a set of 72 non-redundant probe sets (representing 72 unique genes; Table SIV) with the highest average shift from disease centroid towards normal centroid (Data S1). On the microarray platform, the ERM calculated on the 72 probe sets showed a nearly perfect correlation with original ERM values (R 2 = 0Á99; Figure S8 ), indicating the possibility of using a smaller set of genes when implementing ERM. The results produced were consistent across the two platforms ( Figures S9-S14 ).
Multivariate analysis
In multivariate analysis, we first put ERM-D8 together with early prognostic factors like clinical (NCI criteria), biological features (genetics) and Day 8 peripheral blood response (Table II) . ERM-D8 was the strongest prognostic factor in both the training (P = 1Á3 9 10 À3 ; HR 3Á04, 95% CI 1Á55- 6Á07) and the test (P = 0Á03; HR 4Á56, 95% CI 1Á22-17Á12) set. We then added Day 33 MRD, available after end of remission-induction and repeated the multivariate analysis (Table II) . In the training set, ERM-D8 was highly significant (1Á8 9 10 À3 ; HR = 3Á08, 95% CI 1Á52-6Á25), only second to Day 33 MRD. In the test set, ERM-D8 was the only significant prognostic factor (P = 0Á05; HR = 4Á09, 95% CI 1Á03-16Á23). When we included newer genetics features, ERG deletion (as favourable genetics) and BCR-ABL1-like (as unfavourable genetics), into multivariate analyses (Table SV) , similar results were obtained on the training set. On the test set, ERM-D8 remained marginally significant.
Additional value of ERM-D8 to genetics and Day 33 MRD
ERM-D8 significantly improved risk assignment by genetic subgroup (Fig 3A-D) . Patients with favourable genetics but unfavourable ERM-D8 had a significantly higher risk of relapse compared to those with favourable ERM-D8 in both the training set (5-year CIR 37Á5% vs. 0Á0%; P = 3Á7 9 10 À4 ; Fig 3A) and the test set (5-year CIR 28Á6% vs. 0Á0%; P = 0Á01; Fig 3B) . Notably, no patient out of a total of 53 patients with favourable genetics/favourable ERM-D8 relapsed, compared to 11 out of 33 (33Á3%) with favourable genetics/unfavourable ERM-D8. Patients with unfavourable or other genetics but favourable ERM-D8 had less than a half of the risk of those with unfavourable ERM-D8 in the training set (5-year CIR 23Á9% vs. 53Á6%; P = 5Á3 9 10 À3 ; Fig 3C) and the test set (5-year CIR 18Á8% vs. 42Á9%; P = 0Á04; Fig 3D) . The results were similar when new genetic features (ERG deletion and BCR-ABL1-like) were included ( Figure S15 ). ERM-D8 also improved risk stratification in Day 33 MRD positive patients. In the training set, MRD positive patients with unfavourable ERM-D8 had a 5-year CIR of 62Á5%, compared to 34Á9% for patients with favourable ERM-D8 (P = 0Á02; Fig 3G) . In the test set, there was a 6-fold difference in 5-year CIR between ERM-D8 unfavourable and favourable for MRD positive patients (5-year CIR 60Á6% vs. 9Á9%; P = 1Á7 9 10 À3 ; Fig 3H) . When Day 33 MRD was negative, ERM-D8 was predictive of outcome in the training set (5-year CIR 20Á3% vs. 0Á0%; P = 5Á8 9 10 À3 ; Fig 3E) , but not the test set (Fig 3F) . Overall, unfavourable ERM-D8 picked up additional 11 relapses (11/46, 23Á9%) in patients who had achieved CR and were without high risk genetics or Day 33 MRD ( Figure S16 ).
ERM-D8 compared to reported GEP methods
We generated the risk label for our patients using three reported GEP-based risk assignment methods proposed by Holleman et al (2004) , Bhojwani et al (2008) , and Meyer et al (2011) and compared their CIR ( Figure S17 ) against ERM-D8. The only significant risk assignment in the training set was that proposed by Bhojwani et al (2008) .
ERM-D8 defined on leukaemic signatures
We attempted ERM-D8 based on leukaemic gene signatures from diagnostic MILE ALL GEPs (n = 750) in contrast to normal BM GEPs (n = 74). Because the gene signatures were selected from an independent external dataset, there is no risk of overfitting. We applied the selected genes to all the patients with Day 0 and Day 8 GEP pairs (n = 210). In terms of CIR, patients with unfavourable ERM-D8 (n = 92, twice the number of relapses/resistant diseases) have significantly poorer outcome than patients with favourable ERM-D8 (n = 118; 5-year CIR 35Á2% vs. 14Á6%; P = 2Á0 9 10 À4 ; Figure S18 ). The 5-year EFS for unfavourable ERM-D8 was 61Á4%, compared to 83Á7% for favourable ERM-D8 patients (P = 1Á0 9 10 À4 ).
In multivariate analysis (Table SVI) , ERM-D8 remained the most significant prognostic factor (P = 8Á5 9 10 À3 ; HR = 2Á32, 95% CI 1Á24-4Á34) after adjusting for genetics, NCI criteria and Day 8 peripheral blood response. Upon addition to the model, Day 33 MRD emerged as the most important prognostic factor followed by ERM-D8 (P = 0Á04; HR = 2Á05, 95% CI 1Á05-4Á02). ERM-D8 defined on leukaemic signatures also improved risk assignment by genetics and Day 33 MRD ( Figure S18 ).
Discussion
Precise risk-assignment strategies using presenting clinical features, such as age and WBC count, genetic and MRD assays are the cornerstone of contemporary treatment protocols for childhood ALL, leading to a 5-year EFS beyond 80% (Pui et al, 2009 (Pui et al, , 2011 Conter et al, 2010; Yeoh et al, 2012; Mitchell et al, 2014; Vora et al, 2014) . However, patients who lack high-risk genetic features and/or have a good MRD response still account for the majority of relapses. In the Ma-Spore ALL 2003 trial, 75% and 64% of relapses occurred in non-genetic high risk and non-MRD high-risk groups, respectively. The metric, ERM-D8, significantly improved risk assignment by picking up an additional 23Á9% of relapses in patients without high-risk features by genetics, Day 33 MRD or CR status (Figure S16) . Specifically, patients with unfavourable ERM-D8 had significantly higher risk of relapse in all genetic groups. Remarkably, no patient with both favourable genetics and ERM-D8 relapsed (n = 53; Fig 3A, B) . Unfavourable ERM-D8 conferred a 6-fold increased risk of relapse for Day 33 MRD positive patients in the test set (Fig 3H) . Time-series GEPs are used in cell lines exposed to various treatments to elucidate their mechanisms of resistance. Our assay, ERM-D8, assesses these changes in vivo by measuring their magnitude in multi-dimensional gene space towards the normal centroid (Fig 1) . In multivariate analysis, ERM-D8 was tested against current prognostic factors available early during remission induction therapy: NCI criteria, genetic Table II . Multivariate competing risk regression analyses comparing ERM-D8 against genetics, NCI criteria (Smith et al, 1996) consistently performed the best (P = 1Á3 9 10 À3 , 0Á03 and 1Á1 9 10 À4 on the training, test and combined set, respectively; Table II ). Even after adding Day 33 MRD, a late prognostic factor available after end of remission-induction, ERM-D8 remained significant (P = 1Á8 9 10
À3
, 0Á05 and 4Á0 9 10 À4 on the training, test and combined set, respectively; Table II) . PCR-based Day 8 MRD ( Figure S1 ) was measured in 75 randomly selected patients, which indicated that it was not useful in predicting relapse (P = 0Á64; Figure S1B ) as its value remained high in most of the patients. On the other hand, ERM-D8 was predictive of outcome on the same group of patients (P = 7Á3 9 10 À3 ; Figure S1D ). We conclude that ERM-D8 is not the same as PCR-based MRD at Day 8. Day 8 BM blast count did not predict outcome in our cohort, either ( Figure S2 ).
Various groups have attempted to use GEP at diagnosis to predict relapse (Holleman et al, 2004; Bhojwani et al, 2008; Meyer et al, 2011) . The application of the methods used by these three groups to our cohort, did not enable us to independently predict the risk of relapse (Figure S17), although it was possible using ERM-D8. ERM-D8 does not require prior characterization of patient-specific aberrant antigen expression on the leukaemic blasts at diagnosis and can be automated as it is based on a machine-learning platform. Although we have shown the value of ERM-D8 in relapse prediction in three cohorts of patients, this is worth replicating in a larger cohort and ideally in cohorts treated with different treatment protocols. Interestingly, ERM-D8 defined on leukaemic gene signatures derived purely from diagnostic and normal BM GEPs still independently predicted outcome (P = 8Á5 9 10 À3 ; Table SVI) after adjusting for genetics, NCI criteria and Day 8 peripheral blood response. We postulate that, although the optimal gene signature may differ slightly between different treatment protocols, ERM-D8 can be applied in assessment of treatment response in various haematological malignancies. High levels of MRD of >1% early at Day 19 of remission induction adversely affect outcome (Pui et al, 2015) , indicating intrinsic resistance already exists upfront. Early accurate assessments of response create a valuable window for treatment intensification and novel therapy windows. Using ERM, patients could be stratified by D8, allowing potential early optimisation of remission induction therapy. With the US Food and Drug Administration (FDA) approval of tisagenlecleucel, a novel chimeric antigen receptor (CAR)-T cell therapy against CD19 (FDA, 2017) , high risk patients can have their autologous T cells harvested early by end of induction and banked for potential CAR-T therapy later, avoiding T cell damage by multiple cycles of high dose chemotherapy. ERM-D8 can help refine current risk assignment, like genetics and MRD. Patients with unfavourable ERM-D8 but favourable genetics should not receive decelerated therapy. The ALL Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP)-BFM 2000 study showed that even a modest 30% deceleration of delayed intensification from Protocol II to Protocol III resulted in increased risk of relapse in the best risk group of MRD-standard risk patients (Schrappe et al, 2016) . Clearly, MRD alone is insufficient to identify the optimal group for decelerated delayed intensification; ERM-D8 may be useful to identify the best risk patients. Patients with the triple favourable features of ERM-D8, cytogenetics and MRD negativity have an exceedingly low risk of relapse and may benefit from decelerated therapy.
Based on GO and KEGG pathway analyses (Tables SII-SIII and Figures S4, S6-S7) , ERM-D8 is the integrated sum of the top pathways in cell proliferation -DNA, chromosomal and nuclear metabolism. Being a measure of cell proliferation, it is an exceedingly early response measure to treatment and therefore can be applied early by Day 8 of remission induction. Unlike MRD, which measures the percentage of surviving lymphoblasts in the background of normal cells after therapy, ERM-D8 measures the degree of inhibition of vital cell proliferation network. The stronger the inhibition of this network at Day 8, the better the response of treatment and better prognosis.
Consistently, most of the genes involved in DNA replication and cell cycle were found be down-regulated in ERM-D8 favourable patients ( Figures S6-S7 ). One gene, PCNA, was found to play important roles in cell cycle regulation and cellular survival control (Strzalka & Ziemienowicz, 2011) . The high expression of PCNA has been associated with high proliferation of leukaemic cells (Giordano et al, 1991; Tsurusawa et al, 1992) . The down regulation of PCNA at protein level in BM samples from 43 ALL patients has been validated to be prognostic at Day 8 in our Ma-Spore 2003 cohort (Jiang et al, 2011) . Understanding the function of those genes will be the focus of our future investigation, as cell cycle or DNA replication-mediated drug resistance may be overcome with novel drug combination strategy.
Despite it being probably the largest number of time-series GEP applied clinically on a group of children with ALL, ERM-D8 needs to be replicated in other studies. Because ERM-D8 is highly predictive and significantly improves risk assignment based on to the genetic and MRD stratification of current Figure S19 .
In conclusion, we developed a novel metric, ERM-D8, based on time-series GEP, which is highly predictive of treatment outcome. ERM-D8 is independently prognostic of treatment outcome after controlling for contemporary riskassignment factors that included genetics and MRD.
